Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of obeticholic acid tablets for primary biliary cholangitis
CTR20233711Phase 3Terminated
- Sponsor
- Hangzhou Minsheng Pharmaceutical Group
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Hangzhou Minsheng Pharmaceutical Group. Started Nov 2023; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20233711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233711.